CD200: OX-2 membrane glycoprotein
Costimulates T-cell proliferation.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CD200, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Samalizumab | Phase 2 | AstraZeneca Pharmaceuticals | Antibody | InhibitorOX-2 membrane glycoprotein inhibitor | 1 |
| Trial | Drug | Phase | Status | Lead sponsor | First posted |
|---|---|---|---|---|---|
| Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | Samalizumab | Phase 2 / Phase 3 | Recruiting | Beat AML, LLC | Jan 9, 2017 |
- Actinic keratosis0.35
- Skin cancer0.35
- Basal cell carcinoma0.34
- Skin neoplasm0.34
- Ulcerative colitis0.32
- Crohn disease0.32
- Dermatomycosis0.31
- Colonic neoplasm0.30
- Cutaneous melanoma0.30
- Anus neoplasm0.30
- Rectal neoplasm0.30
- Sarcoidosis0.27
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712870, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P41217, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets